Michael Mullan Selected Research

nilvadipine (Escor)

1/2020	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
1/2018	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
1/2016	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.
12/2014	The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.
10/2014	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Mullan Research Topics

Disease

53	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2002
8	Cognitive Dysfunction 01/2020 - 01/2002
7	Inflammation (Inflammations) 01/2022 - 04/2002
7	Brain Concussion (Cerebral Concussion) 01/2019 - 04/2014
7	Amyloid Plaque 01/2010 - 09/2003
6	Neuroinflammatory Diseases 01/2022 - 01/2013
5	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 10/2021 - 01/2014
4	Memory Disorders (Memory Loss) 01/2022 - 12/2004
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 01/2018
4	Wounds and Injuries (Trauma) 01/2019 - 01/2014
4	Gliosis 01/2019 - 02/2006
4	Dementia (Dementias) 01/2018 - 11/2002
3	Hypertension (High Blood Pressure) 01/2018 - 12/2004
2	Fatigue 01/2021 - 01/2020
2	Demyelinating Diseases (Demyelinating Disease) 01/2016 - 04/2014
2	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2014 - 01/2012
2	Neuroblastoma 09/2008 - 04/2002
2	Neoplasms (Cancer) 05/2005 - 05/2004
1	Craniocerebral Trauma (Head Injury) 10/2021
1	Pain (Aches) 01/2021
1	Chronic Pain 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Headache (Headaches) 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2021
1	Neurobehavioral Manifestations 01/2021
1	Weight Loss (Weight Reduction) 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Frailty 01/2016
1	Tauopathies 01/2015
1	Amyloidosis 01/2015
1	Breast Neoplasms (Breast Cancer) 10/2013
1	Glioma (Gliomas) 08/2010

Drug/Important Bio-Agent (IBA)

16	Amyloid beta-PeptidesIBA 12/2019 - 09/2002
12	Apolipoproteins E (ApoE)IBA 01/2021 - 01/2002
12	Peptides (Polypeptides)IBA 06/2011 - 09/2002
11	Amyloid (Amyloid Fibrils)IBA 12/2018 - 07/2004
10	ApolipoproteinsIBA 11/2020 - 01/2002
9	Proteins (Proteins, Gene)FDA Link 10/2013 - 09/2003
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2012
5	LipidsIBA 01/2022 - 01/2018
5	nilvadipine (Escor)IBA 01/2020 - 10/2014
5	anatabineIBA 01/2017 - 11/2011
4	salicylhydroxamic acid (SHAM)IBA 10/2021 - 04/2014
4	Protein Isoforms (Isoforms)IBA 11/2020 - 11/2002
4	1,4-dihydropyridine (dihydropyridine)IBA 01/2020 - 06/2011
4	Phospholipids (Phosphatides)FDA LinkGeneric 01/2019 - 12/2014
4	CD40 Ligand (CD40L)IBA 09/2008 - 07/2004
3	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2020 - 04/2012
3	CytokinesIBA 01/2018 - 01/2013
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 02/2011 - 05/2005
2	Docosahexaenoic AcidsIBA 01/2022 - 01/2017
2	Arachidonic Acid (Vitamin F)IBA 01/2022 - 01/2017
2	Metalloproteases (Metalloproteinases)IBA 01/2021 - 11/2020
2	Syk KinaseIBA 01/2019 - 01/2017
2	Apolipoprotein E4IBA 01/2019 - 01/2013
2	Ether (Diethyl Ether)IBA 01/2016 - 12/2014
2	Antihypertensive Agents (Antihypertensives)IBA 06/2011 - 11/2009
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2009 - 04/2002
1	Lipase (Acid Lipase)FDA Link 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022
1	Biotin (Vitamin H)FDA Link 10/2021
1	Caveolin 1IBA 10/2021
1	Angiopoietin-1IBA 10/2021
1	Eukaryotic Initiation Factor-2 (EIF 2)IBA 01/2021
1	OxylipinsIBA 01/2021
1	Hazardous Substances (Hazardous Materials)IBA 01/2021
1	nicotinamide-beta-ribosideIBA 01/2020
1	SirtuinsIBA 01/2020
1	Sirtuin 1IBA 01/2020
1	Lipoprotein Receptors (Lipoprotein Receptor)IBA 12/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019
1	Apolipoprotein E3IBA 01/2019
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Biological ProductsIBA 01/2018
1	oleoylethanolamideIBA 01/2018
1	erucylphosphocholineIBA 01/2016
1	EpitopesIBA 12/2014
1	Retinaldehyde (Retinal)IBA 04/2014
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2014
1	CorticosteroneIBA 01/2014
1	Desvenlafaxine Succinate FDA Link 10/2013
1	Venlafaxine Hydrochloride (Effexor)FDA LinkGeneric 10/2013
1	Pharmaceutical PreparationsIBA 10/2013
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 10/2013
1	Rhodamine 123IBA 10/2013
1	AlkaloidsIBA 11/2011
1	matrigelIBA 08/2010
1	CreatinineIBA 11/2009
1	Triglycerides (Triacylglycerol)IBA 11/2009

Therapy/Procedure

3	Therapeutics 01/2019 - 06/2011
1	Drug Therapy (Chemotherapy) 10/2021
1	Euthanasia (Mercy Killing) 01/2020
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2019
1	Treatment Delay 01/2017
1	Duration of Therapy 10/2014